AMR threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi. AMR occurs when bacteria, parasites, viruses and fungi change over time and no longer respond to antimicrobials, which makes it harder to treat and increases the risk of diseases spreading. Medicines become ineffective and infections persist in the body (increasing risk of spreading to others). Antimicrobials are medicines used to prevent and treat infections in humans, animals and plants.
AMR, which occurs naturally in bacteria, gets worse over time as one takes more and more antibiotics. Common misconception: humans are not the ones that become resistant to the antibiotic, that specific bacteria become resistant. The problem with such a case is the fact that resistant bacteria are easily contracted making it simpler to infect people and animals. In the case of this experience, some bacteria can be so resistant that there are no antibiotics doctors can use to treat the bacteria. The term we use to define these resistant bacteria is known as superbugs. Other names do include multi-resistant organisms (MROs) and multidrug-resistant organisms (MDRs).
It has emerged as one of the principal public health problems of the 21st century. Several studies have shown that high antibiotic resistance rate with cancer patients when using chemotherapy-related neutropenia, AMR bacteria being in high volumes during liver transplants, and AMR bacteria in neonatal intensive care is becoming impossible to treat.
The CDC estimates that more than 2.8 million people are affected in some sort of way by AMR annually in the 21st century. Costs in the United States alone to treat AMR are upwards of $18,000 per patient. This sums up to more than $4.6 billion spent every year by the federal government of America to tackle this extreme problem.
By 2050, it is estimated that more than 10 million people will be dying every single year causing a Gross Domestic Reduction to ~3.5%. Putting this out in dollars would cost the world up to $100 trillion USD. Resistance of special bacterias is reaching rates >50%. Although this is often overlooked, AMR does pose a huge threat to economies. In the coming decades, AMR will inflict a ton of damage on global economic output. This is our exact mission here at Neuvae. We want to create a Neuvae to the future of AMR and our healthcare system through moonshot technologies such as phage therapy.
